Developer docs
API playgroundTry for free, no card

Search company profiles

Primaa

Full company profile

uuid002leay

Namestring
Primaa
Legal namestring
Primaa SAS
Websiteurl
primaalab.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Primaa SAS is a Paris-based medical imaging AI company founded in 2018 by pathologist Marie Sockeel, along with co-founders Fanny Sockeel (CEO) and Stéphane Sockeel (CSO). The company develops the Cleo platform, a deep-learning software suite that analyzes digitized Whole Slide Images (WSI) of histopathological tissue to detect and quantify cancer biomarkers. Its commercial portfolio consists of two CE-IVDR marked products: Cleo Breast (breast cancer diagnostics, CE-IVDR certified September 2025) and Cleo Skin (dermatopathology AI, CE-IVDR certified March 2026 as the world's first AI tool in that category). The technology stack combines convolutional neural networks (EfficientNet, RetinaNet) for detection and classification, U-Net architectures for tissue and nuclei segmentation, and a proprietary CycleGAN-based stain adaptation methodology for generalization across scanners and staining protocols. End-to-end pipelines detect invasive carcinoma regions directly on IHC slides without pathologist pre-selection, and compute automated scores for HER2, Ki67, ER/RP, TILs, mitoses, and skin lesion dimensions and margins.

The company monetizes through enterprise software licensing (annual site licenses for hospitals and laboratories) and through technology partnership licensing with digital pathology Image Management System (IMS) providers. Its go-to-market combines direct enterprise sales in Europe with an OEM/embedded distribution model in which Cleo algorithms are integrated into third-party IMS platforms — PathAI's AISight Dx, Proscia's Concentriq, PathPresenter, Gestalt's PathFlow, Lumea's IMS Viewer+, and Sectra. Reported customers include 10+ laboratories and clinics with over 45 users, including Institut Curie, AP-HP, Hôpital Saint-Joseph, Institut Bergonié, multiple French university hospital centers (CHU de Rennes, CHU de Versailles, CHU Grenoble Alpes), Medipath, and ZAS in Belgium, with first US commercial contracts signed in 2025–2026.

Primaa is privately held, has approximately 25 employees, and is based in Paris with its legal entity registered in Orsay, France. Total disclosed funding is approximately €7 million raised in an October 2025 pre-Series A round, backed by Elaia, Malakoff Humanis, Super Capital VC, and Swen Capital Partners, with earlier participation from 50 Partners, Matmut, Pleiade Investissement, Bpifrance, and Elaia. The capital is earmarked for US market entry, FDA certification, and extension of the AI roadmap into additional cancer types including kidney (PD-L1 scoring under the CARE1 trial).

Short descriptiontext

Primaa is a Paris-based medical imaging AI company that develops CE-IVDR certified deep learning software for pathologists to detect cancer biomarkers in breast and skin tissue slides, selling enterprise site licenses and OEM-embedded algorithms to hospitals and digital pathology platform providers across Europe and the US.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology software, cancer biomarker detection, AI dermatopathology, breast cancer diagnosis, whole slide imaging
Industry4 codes
PRIMARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAKACAC
Dermatopathology
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
NAICS code1 code
  • Software Publishers513210
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Digital Pathology Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1AI Software Licensing
TypeSubscription Recurring
Description

Enterprise licensing of AI diagnostic software (Cleo Breast, Cleo Skin) to hospitals, cancer institutes, and pathology laboratories. Software is integrated into laboratory viewing systems and sold as annual or multi-year subscriptions. Revenue derived from per-laboratory or per-installation licensing fees.

primaalab.com
2Technology Partnership Licensing
TypeLicensing Royalties
Description

Licensing of AI algorithms to digital pathology platform providers (Proscia, PathAI, PathPresenter, Gestalt) for integration into their IMS platforms. Revenue generated through technology integration agreements and per-use licensing.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Pricing details1 tier
1Enterprise site license for laboratory/pathology department
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for institutional deployments. Annual or multi-year subscription model for laboratory-wide deployment.

primaalab.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Cleo Breast
Description

AI-powered primary diagnostic solution for breast cancer diagnosis, CE-IVDR marked, detecting invasive and in situ carcinoma, mitoses, calcifications, and lymph node metastases.

primaalab.com
+1 more record
Core offering1 text field

Primaa develops and sells AI-powered diagnostic software for pathologists, primarily the Cleo platform with two CE-IVDR marked products: Cleo Breast (detects invasive and in situ carcinoma, mitoses, calcifications, and lymph node metastases on breast tissue whole slide images) and Cleo Skin (detects melanoma, squamous cell carcinoma, basal cell carcinoma with automated lesion and margin measurements on skin tissue). The software is sold as enterprise site licenses and is integrated into existing digital pathology Image Management Systems to automate biomarker scoring and speed cancer diagnosis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Detection time reduction: -14% for Invasive & In Situ Carcinoma, -50% for Mitoses, -32% for Macro-Metastases
+7 more records
Product overview1 text field

Primaa develops an AI-based platform called Cleo for automated and accurate cancer diagnosis using image analysis and deep learning. The portfolio consists of two CE-IVDR marked core products: Cleo Breast for breast cancer diagnostics and Cleo Skin for dermatopathology. Cleo Breast detects Invasive & In Situ Carcinoma, mitoses, calcifications, and lymph node metastases, with additional modules for TILs scoring, nuclear atypia, and IHC quantification (Ki67, ER/RP, HER2). Cleo Skin is the world's first CE-IVDR marked AI for dermatopathology, classifying lesions (melanoma, nevus, SCC, BCC), measuring dimensions and margins, and detecting mitoses and perineural invasion. Both products integrate with major digital pathology platforms (Sectra, Gestalt PathFlow, PathAI, Proscia, PathPresenter) and feature vendor-agnostic, interoperable design with smart work list prioritization for laboratory workflows.

Product and service3 records
1Cleo Breast
CategoryAI Diagnostic Software - Breast Pathology
Description

AI-powered primary diagnostic solution for breast cancer, CE-IVDR marked. Detects Invasive & In Situ Carcinoma, mitoses, calcifications, and lymph node metastases on digitized breast tissue Whole Slide Images. Includes automated hotspot detection, IHC quantification (Ki67, ER/RP, HER2), TILs scoring, nuclear atypia analysis, and smart work list prioritization for hospital pathology departments.

2Cleo Skin
CategoryAI Diagnostic Software - Dermatopathology
Description

World's first CE-IVDR marked AI solution for dermatopathology. Detects and classifies skin lesions (melanoma, nevus, squamous cell carcinoma, basal cell carcinoma), automatically measures lesion dimensions and excision margins, detects mitoses and perineural invasion in melanoma regions. Deployed at dermatopathology laboratories and skin cancer diagnostic centers.

3Cleo Platform
CategoryAI Diagnostic Platform
Description

Core AI-based platform for automated and accurate cancer diagnosis using image analysis and deep learning. Improves detection of major cancer biomarkers and guides personalized treatment, providing time-saving workflow integration, performance gains, and enhanced patient outcomes across multiple organ-specific applications.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierKeyTypeTechnology or IntegrationAnnounced on2026-03-24
Description

Partnership integrating Primaa's Cleo Skin AI into Lumea's FDA-cleared IMS Viewer+ platform for dermatopathology diagnostics. Cleo Skin provides automated triage, sub-millimeter measurements, and biomarker detection for the four most common skin lesions.

Strategic tierKeyTypeTechnology or IntegrationAnnounced on2025-11-06
Description

Integration of Cleo Skin AI with PathPresenter's FDA 510(k) and CE-IVDR cleared IMS platform. Makes Cleo Skin available to wider global audience of pathologists through PathPresenter's platform, with demos at ASDP 2025.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-15
Description

Integration of Cleo Skin into Proscia's Concentriq platform through Proscia Ready partner alliance. Adds AI-powered skin biomarker detection (mitoses, mitotic hotspots, perineural invasion) and lesion classification to Concentriq's digital pathology capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-04
Description

Integration of Cleo Breast (CE-IVDR) and Cleo Skin (RUO) into PathAI's AISight Dx Image Management System. Enables pathologists using AISight Dx to access Primaa's AI-powered algorithms for enhanced accuracy and efficiency in breast and skin tissue lesion detection.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-19
Description

Strategic partnership integrating Primaa's Cleo Skin AI into Gestalt's PathFlow digital pathology platform. Enables pathologists to access AI-driven skin cancer detection, lesion classification (melanoma, SCC, BCC), automatic measurements, and case prioritization within PathFlow workflows. Supports primary diagnosis in US (following LDT process) and CE-IVD marking for Europe.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-01
Description

Partnership to advance AI-powered skin cancer detection through integrated digital pathology solutions using Gestalt's platform and Primaa's Cleo Skin technology.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

First international clinical deployment of Cleo Skin at ZAS hospital group in Belgium, representing Primaa's expansion beyond France into European markets.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

US-based IMS vendor (PathFlow) and Primaa integration partner for Cleo Skin. Functions as a regional digital pathology incumbent and distribution partner for US pathology customers.

TypeBroad incumbent
Description

US-based digital pathology software provider (HALO platform) with extensive pharma and research customer base. Broad incumbent offering image analysis with overlapping AI quantification capabilities.

TypeEmerging player
Description

Germany-based AI pathology company with CE-marked breast and prostate IHC quantification products. Comparable as a European peer in AI biomarker scoring, slightly narrower product scope.

TypeDirect peer
Description

US-based AI pathology company; first to receive FDA de novo authorization for an AI pathology product (Paige Prostate) and expanding into breast and dermatopathology. Comparable in target market and AI-on-WSI technology.

TypeBroad incumbent
Description

US-based digital pathology platform provider (Concentriq) and Proscia Ready partner alliance host. Functions as both a distribution partner (embedding Primaa) and a broader incumbent that develops its own AI roadmap.

TypeEmerging player
Description

Netherlands-based AI pathology company focused on kidney and breast biomarker quantification. Comparable as a European emerging peer in IHC and biomarker AI.

TypeEmerging player
Description

US-based FDA-cleared digital pathology platform (Viewer+) with strong dermatopathology focus. Embedded Primaa Cleo Skin via marketplace integration; comparable in dermatopathology target segment.

TypeDirect peer
Description

France-based AI company building pathology AI models for pharma services and diagnostics, with strong federated learning capabilities. Comparable as a French AI pathology peer and competitor for hospital and pharma customers.

TypeDirect peer
Description

US-based AI pathology company developing both AI algorithms and the AISight Dx Image Management System. Direct competitor in breast and dermatopathology AI, and simultaneously a distribution partner for Primaa's Cleo modules.

TypeDirect peer
Description

Israel-based AI pathology company with multiple CE-marked products (Galen Breast, Galen Prostate, Galen Gastric) and strong clinical deployments. Directly comparable in product scope (multi-organ AI on WSIs) and customer base (hospital pathology labs).

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration19 records

Each record includes

Title, Type, Description, Source

AI capability20 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Primaa

Digital Pathology Softwareprimaalab.com

Primaa is a Paris-based medical imaging AI company that develops CE-IVDR certified deep learning software for pathologists to detect cancer biomarkers in breast and skin tissue slides, selling enterprise site licenses and OEM-embedded algorithms to hospitals and digital pathology platform providers across Europe and the US.

What Primaa does

Primaa SAS is a Paris-based medical imaging AI company founded in 2018 by pathologist Marie Sockeel, along with co-founders Fanny Sockeel (CEO) and Stéphane Sockeel (CSO). The company develops the Cleo platform, a deep-learning software suite that analyzes digitized Whole Slide Images (WSI) of histopathological tissue to detect and quantify cancer biomarkers. Its commercial portfolio consists of two CE-IVDR marked products: Cleo Breast (breast cancer diagnostics, CE-IVDR certified September 2025) and Cleo Skin (dermatopathology AI, CE-IVDR certified March 2026 as the world's first AI tool in that category). The technology stack combines convolutional neural networks (EfficientNet, RetinaNet) for detection and classification, U-Net architectures for tissue and nuclei segmentation, and a proprietary CycleGAN-based stain adaptation methodology for generalization across scanners and staining protocols. End-to-end pipelines detect invasive carcinoma regions directly on IHC slides without pathologist pre-selection, and compute automated scores for HER2, Ki67, ER/RP, TILs, mitoses, and skin lesion dimensions and margins.

The company monetizes through enterprise software licensing (annual site licenses for hospitals and laboratories) and through technology partnership licensing with digital pathology Image Management System (IMS) providers. Its go-to-market combines direct enterprise sales in Europe with an OEM/embedded distribution model in which Cleo algorithms are integrated into third-party IMS platforms — PathAI's AISight Dx, Proscia's Concentriq, PathPresenter, Gestalt's PathFlow, Lumea's IMS Viewer+, and Sectra. Reported customers include 10+ laboratories and clinics with over 45 users, including Institut Curie, AP-HP, Hôpital Saint-Joseph, Institut Bergonié, multiple French university hospital centers (CHU de Rennes, CHU de Versailles, CHU Grenoble Alpes), Medipath, and ZAS in Belgium, with first US commercial contracts signed in 2025–2026.

Primaa is privately held, has approximately 25 employees, and is based in Paris with its legal entity registered in Orsay, France. Total disclosed funding is approximately €7 million raised in an October 2025 pre-Series A round, backed by Elaia, Malakoff Humanis, Super Capital VC, and Swen Capital Partners, with earlier participation from 50 Partners, Matmut, Pleiade Investissement, Bpifrance, and Elaia. The capital is earmarked for US market entry, FDA certification, and extension of the AI roadmap into additional cancer types including kidney (PD-L1 scoring under the CARE1 trial).

Primaa firmographics

Firmographics
Name
Primaa
Legal name
Primaa SAS
Website
https://primaalab.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Primaa is a Paris-based medical imaging AI company that develops CE-IVDR certified deep learning software for pathologists to detect cancer biomarkers in breast and skin tissue slides, selling enterprise site licenses and OEM-embedded algorithms to hospitals and digital pathology platform providers across Europe and the US.
Ownership category
akta.pro rank

Primaa industry classification

Industry
Product category
Digital Pathology Software
NAICS
Software Publishers (513210)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAKACAC
Dermatopathology
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability

Keywords

  • Digital pathology software
  • Cancer biomarker detection
  • AI dermatopathology
  • Breast cancer diagnosis
  • Whole slide imaging

Where Primaa is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Primaa business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. AI Software Licensing: Enterprise licensing of AI diagnostic software (Cleo Breast, Cleo Skin) to hospitals, cancer institutes, and pathology laboratories. Software is integrated into laboratory viewing systems and sold as annual or multi-year subscriptions. Revenue derived from per-laboratory or per-installation licensing fees.
  2. Technology Partnership Licensing: Licensing of AI algorithms to digital pathology platform providers (Proscia, PathAI, PathPresenter, Gestalt) for integration into their IMS platforms. Revenue generated through technology integration agreements and per-use licensing.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise site license for laboratory/pathology department

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Primaa product offering

Product offering

Core offering

Primaa develops and sells AI-powered diagnostic software for pathologists, primarily the Cleo platform with two CE-IVDR marked products: Cleo Breast (detects invasive and in situ carcinoma, mitoses, calcifications, and lymph node metastases on breast tissue whole slide images) and Cleo Skin (detects melanoma, squamous cell carcinoma, basal cell carcinoma with automated lesion and margin measurements on skin tissue). The software is sold as enterprise site licenses and is integrated into existing digital pathology Image Management Systems to automate biomarker scoring and speed cancer diagnosis.

Product overview

Primaa develops an AI-based platform called Cleo for automated and accurate cancer diagnosis using image analysis and deep learning. The portfolio consists of two CE-IVDR marked core products: Cleo Breast for breast cancer diagnostics and Cleo Skin for dermatopathology. Cleo Breast detects Invasive & In Situ Carcinoma, mitoses, calcifications, and lymph node metastases, with additional modules for TILs scoring, nuclear atypia, and IHC quantification (Ki67, ER/RP, HER2). Cleo Skin is the world's first CE-IVDR marked AI for dermatopathology, classifying lesions (melanoma, nevus, SCC, BCC), measuring dimensions and margins, and detecting mitoses and perineural invasion. Both products integrate with major digital pathology platforms (Sectra, Gestalt PathFlow, PathAI, Proscia, PathPresenter) and feature vendor-agnostic, interoperable design with smart work list prioritization for laboratory workflows.

Differentiator

Problem solved

Functional benefit

Brands

  • Cleo Breast: AI-powered primary diagnostic solution for breast cancer diagnosis, CE-IVDR marked, detecting invasive and in situ carcinoma, mitoses, calcifications, and lymph node metastases.
  • Cleo Skin

Products and services

  • Cleo Breast AI-powered primary diagnostic solution for breast cancer, CE-IVDR marked. Detects Invasive & In Situ Carcinoma, mitoses, calcifications, and lymph node metastases on digitized breast tissue Whole Slide Images. Includes automated hotspot detection, IHC quantification (Ki67, ER/RP, HER2), TILs scoring, nuclear atypia analysis, and smart work list prioritization for hospital pathology departments.
  • Cleo Skin World's first CE-IVDR marked AI solution for dermatopathology. Detects and classifies skin lesions (melanoma, nevus, squamous cell carcinoma, basal cell carcinoma), automatically measures lesion dimensions and excision margins, detects mitoses and perineural invasion in melanoma regions. Deployed at dermatopathology laboratories and skin cancer diagnostic centers.
  • Cleo Platform Core AI-based platform for automated and accurate cancer diagnosis using image analysis and deep learning. Improves detection of major cancer biomarkers and guides personalized treatment, providing time-saving workflow integration, performance gains, and enhanced patient outcomes across multiple organ-specific applications.

Quantifiable outcome

  • Detection time reduction: -14% for Invasive & In Situ Carcinoma, -50% for Mitoses, -32% for Macro-Metastases
  • +7 more outcomes

Companies that use Primaa

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Primaa technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration19 records

AI capability20 records

Feature8 records

Primaa partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered key and core.

  • LumeakeyTechnology or Integration · 24 March 2026Partnership integrating Primaa's Cleo Skin AI into Lumea's FDA-cleared IMS Viewer+ platform for dermatopathology diagnostics. Cleo Skin provides automated triage, sub-millimeter measurements, and biomarker detection for the four most common skin lesions.
  • PathPresenterkeyTechnology or Integration · 6 November 2025Integration of Cleo Skin AI with PathPresenter's FDA 510(k) and CE-IVDR cleared IMS platform. Makes Cleo Skin available to wider global audience of pathologists through PathPresenter's platform, with demos at ASDP 2025.
  • ProsciacoreTechnology or Integration · 15 October 2025Integration of Cleo Skin into Proscia's Concentriq platform through Proscia Ready partner alliance. Adds AI-powered skin biomarker detection (mitoses, mitotic hotspots, perineural invasion) and lesion classification to Concentriq's digital pathology capabilities.
  • PathAIcoreTechnology or Integration · 4 September 2025Integration of Cleo Breast (CE-IVDR) and Cleo Skin (RUO) into PathAI's AISight Dx Image Management System. Enables pathologists using AISight Dx to access Primaa's AI-powered algorithms for enhanced accuracy and efficiency in breast and skin tissue lesion detection.
  • Gestalt DiagnosticscoreTechnology or Integration · 19 March 2025Strategic partnership integrating Primaa's Cleo Skin AI into Gestalt's PathFlow digital pathology platform. Enables pathologists to access AI-driven skin cancer detection, lesion classification (melanoma, SCC, BCC), automatic measurements, and case prioritization within PathFlow workflows. Supports primary diagnosis in US (following LDT process) and CE-IVD marking for Europe.
  • Gestalt DiagnosticscoreTechnology or Integration · 1 March 2025Partnership to advance AI-powered skin cancer detection through integrated digital pathology solutions using Gestalt's platform and Primaa's Cleo Skin technology.
  • ZAS (Belgium)keyStrategic or Co-development PartnerFirst international clinical deployment of Cleo Skin at ZAS hospital group in Belgium, representing Primaa's expansion beyond France into European markets.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Primaa competitors and assessment

Company assessment

Regional players

  • Gestalt Diagnostics: US-based IMS vendor (PathFlow) and Primaa integration partner for Cleo Skin. Functions as a regional digital pathology incumbent and distribution partner for US pathology customers.

Broad incumbents

  • Indica Labs: US-based digital pathology software provider (HALO platform) with extensive pharma and research customer base. Broad incumbent offering image analysis with overlapping AI quantification capabilities.
  • Proscia: US-based digital pathology platform provider (Concentriq) and Proscia Ready partner alliance host. Functions as both a distribution partner (embedding Primaa) and a broader incumbent that develops its own AI roadmap.

Emerging players

  • Mindpeak: Germany-based AI pathology company with CE-marked breast and prostate IHC quantification products. Comparable as a European peer in AI biomarker scoring, slightly narrower product scope.
  • Aiosyn: Netherlands-based AI pathology company focused on kidney and breast biomarker quantification. Comparable as a European emerging peer in IHC and biomarker AI.
  • Lumea: US-based FDA-cleared digital pathology platform (Viewer+) with strong dermatopathology focus. Embedded Primaa Cleo Skin via marketplace integration; comparable in dermatopathology target segment.

Direct peers

  • Paige: US-based AI pathology company; first to receive FDA de novo authorization for an AI pathology product (Paige Prostate) and expanding into breast and dermatopathology. Comparable in target market and AI-on-WSI technology.
  • Owkin: France-based AI company building pathology AI models for pharma services and diagnostics, with strong federated learning capabilities. Comparable as a French AI pathology peer and competitor for hospital and pharma customers.
  • PathAI: US-based AI pathology company developing both AI algorithms and the AISight Dx Image Management System. Direct competitor in breast and dermatopathology AI, and simultaneously a distribution partner for Primaa's Cleo modules.
  • Ibex Medical Analytics: Israel-based AI pathology company with multiple CE-marked products (Galen Breast, Galen Prostate, Galen Gastric) and strong clinical deployments. Directly comparable in product scope (multi-organ AI on WSIs) and customer base (hospital pathology labs).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Primaa social profiles

Digital presence

Primaa compliance and trust

Trust signal

Compliance4 records

Primaa financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Primaa leadership team

Management profile

Number of profiles

Profiles9 records

Primaa funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Primaa M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Primaa

What does Primaa do?

Primaa develops and sells AI-powered diagnostic software for pathologists, primarily the Cleo platform with two CE-IVDR marked products: Cleo Breast (detects invasive and in situ carcinoma, mitoses, calcifications, and lymph node metastases on breast tissue whole slide images) and Cleo Skin (detects melanoma, squamous cell carcinoma, basal cell carcinoma with automated lesion and margin measurements on skin tissue). The software is sold as enterprise site licenses and is integrated into existing digital pathology Image Management Systems to automate biomarker scoring and speed cancer diagnosis.

Is Primaa a public or private company?

Primaa is a private company. It is classified as venture growth investor backed and is currently operating.

When was Primaa founded?

Primaa was founded in 2018. It employs 11 to 50 people.

Where is Primaa based?

Primaa is headquartered in Paris, France, in the Europe region.

How does Primaa make money?

Two revenue lines are on record. AI Software Licensing is the primary driver. The others are technology Partnership Licensing.

Who are Primaa's main competitors?

Gestalt Diagnostics is listed as a regional player. Broad incumbents are Indica Labs and Proscia. Emerging players are Mindpeak, Aiosyn and Lumea. Direct peers are Paige, Owkin, PathAI and Ibex Medical Analytics.

Does Primaa have an API?

No public API is recorded for Primaa.

What industry is Primaa in?

Primaa's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comSkin Cancer Diagnostics Market Trends Support A 8.6% CAGR Outlook Through The Forecast PeriodThe skin cancer diagnostics market is projected to reach $5.09 billion by 2030, growing at an 8.6% CAGR. Growth is driven by AI and molecular diagnostics, with a March 2025 partnership between Gestalt Diagnostics and Primaa to enhance skin cancer detection.openPR.comEmerging Sub-Segments Transforming the Skin Cancer Diagnostics Market LandscapeThe skin cancer diagnostics market is projected to grow to $5.09 billion by 2030 at a compound annual growth rate of 8.6%, driven by AI adoption, advanced imaging, and teledermatology services. In March 2025, Gestalt Diagnostics partnered with Primaa to advance AI-powered skin cancer detection through integrated digital pathology solutions. Additionally, Skin Check Champions, in collaboration with the University of South Australia and The Hospital Research Foundation, launched an AI-powered pop-up clinic in January 2023 to improve skin cancer diagnosis access in Australia.EIN PresswireLumea Partners with Primaa to Expand Dermatopathology Offerings with Cleo Skin AILumea, a U.S. leader in primary clinical digital pathology, has partnered with Primaa to integrate Primaa's Cleo Skin AI solution into Lumea's FDA-cleared IMS Viewer+ platform for dermatopathology diagnostics. Cleo Skin is the first AI tool worldwide designed specifically to assist in diagnosing the four most common skin lesions, offering automated triage, sub-millimeter measurements, and biomarker detection. The open marketplace integration allows labs to adopt the technology without changing their existing LIS or scanning hardware, expanding Lumea's diagnostic ecosystem for dermatology groups.LumeadigitalTop AI Companies for Digital Derm PathologyThis article provides an overview of leading AI companies providing digital solutions for dermatopathology, highlighting how these tools assist pathologists in diagnosing skin conditions through automated analysis of histological images. Primaa's Cleo Skin offers primary diagnostic assistance for skin cancer detection, while aisencia's Cutaneous80 covers over 40 skin conditions including both common and rare lesions. The article also notes emerging solutions like HistoGPT from Helmholtz Munich and TUM, which uses vision-language models to draft pathology reports, addressing efficiency challenges in labs facing high biopsy volumes and limited specialist availability.The French Tech Journal👻 French Tech Wire: France Spooked By Fears Of Great Founder MigrationFrance is facing growing concerns about tech founders emigrating to the United States, with Digital Minister Anne Le Hénanff urging entrepreneurs to stay and promising to protect startup support schemes amid budget cuts. Criteo, once a flagship of French tech, announced it is relocating its legal headquarters from France to Luxembourg en route to the United States in 2027. Several French tech companies made headlines, including Doctolib announcing profitability after 12 years, while funding rounds went to Onepark (€40M), Primaa (€7M), and World Fund announced a €300M push into French climate tech startups.FRENCHWEB.FRComment l’intelligence artificielle transforme le diagnostic anatomopathologiquePrimaa, a Paris-based healthtech startup founded in 2018, has developed an AI platform that analyzes histological tissue images to detect breast and skin cancers, standardizing diagnostic readings and reducing variability between pathologists. The company has raised €7 million in funding from investors including MH Innov', Elaia, SWEN Capital Partners, Super Capital, and members of the Wendel family. The capital will be used to expand commercial and technical teams, accelerate new AI module development, and pursue FDA certification for entry into the US market.Tech.euPrimaa raises €7M to accelerate product growth and international expansionParis-based Primaa, a developer of AI software for automated histological and cancer diagnostics, has extended its financing round to €7 million, backed by MH Innov'/Elaia partnership fund, SWEN Capital Partners, Super Capital, and members of the Wendel family. The company produces Cleo Breast and Cleo Skin, which are deployed at leading French medical centers including Institut Curie, AP-HP, and Saint-Joseph Hospital, and are rolling out across Europe. The new funding will accelerate European sales expansion, support predictive AI model development, and fund planned entry into the United States market with FDA certification activities.